Millennium Management’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-552,166
| Closed | -$21.2M | – | 6821 |
|
|
2023
Q2 | $21.2M | Buy |
552,166
+303,712
| +122% | +$7.8M | 0.01% | 1334 |
|
|
2023
Q1 | $5.75M | Sell |
248,454
-192,284
| -44% | -$4.58M | ﹤0.01% | 2487 |
|
|
2022
Q4 | $11.5M | Buy |
440,738
+41,769
| +10% | +$925K | 0.01% | 1965 |
|
|
2022
Q3 | $7.84M | Sell |
398,969
-786,264
| -66% | -$15.8M | ﹤0.01% | 2448 |
|
|
2022
Q2 | $20.7M | Buy |
1,185,233
+448,094
| +61% | +$7.03M | 0.01% | 1266 |
|
|
2022
Q1 | $12.1M | Buy |
737,139
+386,695
| +110% | +$5.26M | 0.01% | 1937 |
|
|
2021
Q4 | $5.72M | Sell |
350,444
-314,032
| -47% | -$4.47M | ﹤0.01% | 2760 |
|
|
2021
Q3 | $8.48M | Buy |
664,476
+352,915
| +113% | +$4.65M | 0.01% | 2280 |
|
|
2021
Q2 | $4.4M | Sell |
311,561
-97,926
| -24% | -$1.57M | ﹤0.01% | 2923 |
|
|
2021
Q1 | $6.36M | Buy |
409,487
+309,154
| +308% | +$5.04M | ﹤0.01% | 2324 |
|
|
2020
Q4 | $1.59M | Buy |
+100,333
| New | +$1.51M | ﹤0.01% | 3407 |
|
|
2020
Q3 | – | Sell |
-2,334
| Closed | -$27K | – | 4939 |
|
|
2020
Q2 | $27K | Sell |
2,334
-31,627
| -93% | -$436K | ﹤0.01% | 4080 |
|
|
2020
Q1 | $465K | Buy |
33,961
+30,812
| +978% | +$364K | ﹤0.01% | 2928 |
|
|
2019
Q4 | $19K | Sell |
3,149
-36,675
| -92% | -$199K | ﹤0.01% | 4128 |
|
|
2019
Q3 | $211K | Sell |
39,824
-14,079
| -26% | -$93.4K | ﹤0.01% | 3757 |
|
|
2019
Q2 | $415K | Sell |
53,903
-193
| -0.4% | -$2.94K | ﹤0.01% | 3354 |
|
|
2019
Q1 | $1.08M | Buy |
54,096
+30,821
| +132% | +$537K | ﹤0.01% | 2819 |
|
|
2018
Q4 | $307K | Buy |
23,275
+4,662
| +25% | +$93.1K | ﹤0.01% | 3205 |
|
|
2018
Q3 | $684K | Buy |
18,613
+10,537
| +130% | +$338K | ﹤0.01% | 3074 |
|
|
2018
Q2 | $283K | Sell |
8,076
-248,393
| -97% | -$9.52M | ﹤0.01% | 3421 |
|
|
2018
Q1 | $11.9M | Buy |
256,469
+196,781
| +330% | +$7.2M | 0.02% | 1222 |
|
|
2017
Q4 | $2.24M | Buy |
59,688
+2,198
| +4% | +$96K | ﹤0.01% | 2212 |
|
|
2017
Q3 | $3.06M | Buy |
57,490
+46,486
| +422% | +$2.76M | ﹤0.01% | 1947 |
|
|
2017
Q2 | $627K | Sell |
11,004
-4,840
| -31% | -$243K | ﹤0.01% | 2694 |
|
|
2017
Q1 | $852K | Buy |
+15,844
| New | +$895K | ﹤0.01% | 2499 |
|
|
2016
Q3 | – | Sell |
-30,695
| Closed | -$1.74M | – | 3706 |
|
|
2016
Q2 | $1.74M | Buy |
30,695
+19,901
| +184% | +$1.21M | ﹤0.01% | 1857 |
|
|
2016
Q1 | $691K | Buy |
+10,794
| New | +$873K | ﹤0.01% | 2358 |
|
|
2015
Q4 | – | Sell |
-10,051
| Closed | -$973K | – | 3858 |
|
|
2015
Q3 | $973K | Buy |
10,051
+2,051
| +26% | +$244K | ﹤0.01% | 2288 |
|
|
2015
Q2 | $1.21M | Buy |
+8,000
| New | +$1.32M | ﹤0.01% | 2181 |
|
Millennium Management's KDNY Position: Q3 2023 in Review
Millennium Management sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 552,166 shares — an estimated $21.2M sold.
Millennium Management first reported a position in KDNY in Q2 2015 and held it in 29 quarters. The position peaked at $21.2M in Q2 2023. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.
- Millennium Management reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
- Millennium Management sold 552,166 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $21.2M.
- Millennium Management first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2015 and held it in 29 quarters.
- Millennium Management's Chinook Therapeutics, Inc. Common Stock position peaked at $21.2M in Q2 2023.
- 2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.
Based on Millennium Management's 13F filing for Q3 2023, filed 14 Nov 2023.